Carl Sterritt

Founder & CEO at Shield Therapeutics Plc

Carl Sterritt's Professional Contact Details

Email (Verified)

****@shieldtx.com

Get Email Address

+44 191 511 8500

Location

Weybridge, England, United Kingdom

Company

Shield Therapeutics Plc

Person Seniority

founder

Person Functions

entrepreneurship

Carl Sterritt's Current Company Details

Shield Therapeutics Plc

Gateshead, England, United Kingdom • 39 Employees

pharmaceuticals

Shield Therapeutics PLC is a fast growing specialty pharmaceutical company formed in 2008 focusing on the development and commercialisation of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The Company's key products are FeraccruÂ®, for the treatment of iron deficiency anaemia (IDA) in patients with Inflammatory Bowel Disease (IBD) and PT20 (a late stage pharmaceutical) for the treatment of systemic phosphate accumulation (otherwise known as hyperphosphatemia). Feraccru obtained its first marketing authorisation (via the EU centralised procedure) on 18 February 2016, shortly to be followed by a commercial launch in the first Â½ of 2016. The Directors believe Feraccru has an achievable global peak annual sales opportunity in excess of Â£500 million.

Public Symbol

STX

Founded Year

2008

Organization Website

shieldtherapeutics.com

Organization Languages

English

Organization Revenue

12000

Current Technologies

outlook